Hims & Hers Health/$HIMS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Hims & Hers Health

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.

Ticker

$HIMS

Primary listing

NYSE

Industry

Health Care Providers & Services

Employees

1,637

ISIN

US4330001060

HIMS Metrics

BasicAdvanced
$14B
89.57
$0.68
2.10
-

What the Analysts think about HIMS

Analyst ratings (Buy, Hold, Sell) for Hims & Hers Health stock.

Bulls say / Bears say

Hims & Hers Health's acquisition of UK-based startup Zava expands its international presence, particularly in Germany, France, and Ireland, potentially increasing its customer base and revenue streams. (reuters.com)
The company reported a 110.7% year-over-year revenue increase in Q1 2025, reaching $586.01 million, surpassing analyst expectations and indicating strong financial performance. (reuters.com)
Hims & Hers Health's inclusion in the S&P SmallCap 600 index enhances its visibility among investors and may lead to increased stock demand. (reuters.com)
The U.S. FDA's ban on compounded versions of Novo Nordisk's weight-loss drug Wegovy has led Hims & Hers to cut 4% of its workforce, indicating potential challenges in its weight-loss product offerings. (reuters.com)
Citigroup reaffirmed a 'Sell' rating for Hims & Hers Health, suggesting concerns about the company's future performance and potential overvaluation. (marketbeat.com)
The discontinuation of its dermatology business, Apostrophe, may indicate operational challenges and could impact the company's diversification strategy. (businessinsider.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.

HIMS Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

HIMS Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $HIMS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs